» Articles » PMID: 27537821

Gd(III)-Gold Nanoconjugates Provide Remarkable Cell Labeling for High Field Magnetic Resonance Imaging

Overview
Journal Bioconjug Chem
Specialty Biochemistry
Date 2016 Aug 19
PMID 27537821
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In vivo cell tracking is vital for understanding migrating cell populations, particularly cancer and immune cells. Magnetic resonance (MR) imaging for long-term tracking of transplanted cells in live organisms requires cells to effectively internalize Gd(III) contrast agents (CAs). Clinical Gd(III)-based CAs require high dosing concentrations and extended incubation times for cellular internalization. To combat this, we have devised a series of Gd(III)-gold nanoconjugates (Gd@AuNPs) with varied chelate structure and nanoparticle-chelate linker length, with the goal of labeling and imaging breast cancer cells. These new Gd@AuNPs demonstrate significantly enhanced labeling compared to previous Gd(III)-gold-DNA nanoconstructs. Variations in Gd(III) loading, surface packing, and cell uptake were observed among four different Gd@AuNP formulations suggesting that linker length and surface charge play an important role in cell labeling. The best performing Gd@AuNPs afforded 23.6 ± 3.6 fmol of Gd(III) per cell at an incubation concentration of 27.5 μM-this efficiency of Gd(III) payload delivery (Gd(III)/cell normalized to dose) exceeds that of previous Gd(III)-Au conjugates and most other Gd(III)-nanoparticle formulations. Further, Gd@AuNPs were well-tolerated in vivo in terms of biodistribution and clearance, and supports future cell tracking applications in whole-animal models.

Citing Articles

Engineered Nonviral Protein Cages Modified for MR Imaging.

Kaster M, Levasseur M, Edwardson T, Caldwell M, Hofmann D, Licciardi G ACS Appl Bio Mater. 2023; 6(2):591-602.

PMID: 36626688 PMC: 9945100. DOI: 10.1021/acsabm.2c00892.


Multinuclear MRI in Drug Discovery.

Bartusik-Aebisher D, Bober Z, Zalejska-Fiolka J, Kawczyk-Krupka A, Aebisher D Molecules. 2022; 27(19).

PMID: 36235031 PMC: 9572840. DOI: 10.3390/molecules27196493.


Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.

Teleanu R, Preda M, Niculescu A, Vladacenco O, Radu C, Grumezescu A Pharmaceutics. 2022; 14(5).

PMID: 35631573 PMC: 9145636. DOI: 10.3390/pharmaceutics14050987.


Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis.

Luo D, Wang X, Burda C, Basilion J Cancers (Basel). 2021; 13(8).

PMID: 33920453 PMC: 8069007. DOI: 10.3390/cancers13081825.


Dual Imaging Gold Nanoplatforms for Targeted Radiotheranostics.

Silva F, Paulo A, Pallier A, Meme S, Toth E, Gano L Materials (Basel). 2020; 13(3).

PMID: 31978954 PMC: 7040626. DOI: 10.3390/ma13030513.


References
1.
Guenoun J, Koning G, Doeswijk G, Bosman L, Wielopolski P, Krestin G . Cationic Gd-DTPA liposomes for highly efficient labeling of mesenchymal stem cells and cell tracking with MRI. Cell Transplant. 2011; 21(1):191-205. DOI: 10.3727/096368911X593118. View

2.
Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005; 40(11):715-24. DOI: 10.1097/01.rli.0000184756.66360.d3. View

3.
Nicholls F, Rotz M, Ghuman H, MacRenaris K, Meade T, Modo M . DNA-gadolinium-gold nanoparticles for in vivo T1 MR imaging of transplanted human neural stem cells. Biomaterials. 2015; 77:291-306. PMC: 4684435. DOI: 10.1016/j.biomaterials.2015.11.021. View

4.
Skeoch S, Williams H, Cristinacce P, Hockings P, James J, Alexander Y . Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using (18)F-fluorodeoxyglucose PET-CT and MRI: a pilot study. Lancet. 2015; 385 Suppl 1:S91. DOI: 10.1016/S0140-6736(15)60406-8. View

5.
Ranjan Patra C, Bhattacharya R, Wang E, Katarya A, Lau J, Dutta S . Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008; 68(6):1970-8. DOI: 10.1158/0008-5472.CAN-07-6102. View